{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:36:49Z","timestamp":1793313409952,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":506,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015311","name":"Novartis Institutes for BioMedical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020948","name":"AstraZeneca, M\u00f6lndal","doi-asserted-by":"publisher","award":["1377"],"award-info":[{"award-number":["1377"]}],"id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015311","name":"Novartis Institutes for BioMedical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020948","name":"AstraZeneca M\u00f6lndal","doi-asserted-by":"publisher","award":["1377"],"award-info":[{"award-number":["1377"]}],"id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The prevalence of iron deficiency (ID) in newly diagnosed heart failure (HF) and the progression of ID in patients after initiation of HF therapy are unknown. We aimed to describe the natural trajectory of ID in patients with new onset HF during the first year after HF diagnosis, assessing associations between ID, clinical factors, and quality of life (QoL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A prospective cohort of patients with new onset HF in hospitals or outpatient clinics at five major hospitals in Stockholm, Sweden, during 2015\u20132018 were analysed with clinical assessment, electrocardiogram, blood samples including iron levels, Minnesota living with heart failure questionnaire (MLHFQ), and echocardiogram at baseline and after 12 months. Of 547 patients with new-onset HF, 482 (88%) had complete iron data at baseline. Median age was 70 years (interquartile range 61\u201377) and 311 (65%) were men; 55% of patients had ejection fraction (EF) \u2264 40%, 19% had EF 41\u201349%, and 26% had HF with preserved EF (HFpEF) [Correction added on 26 June 2024, after first online publication: The \u2018Mean age was 70 years\u2019 has been corrected to \u2018Median age was 70 years\u2019 in this version.]. At baseline, 163 patients (34%) had ID defined as ferritin &amp;lt;100 \u03bcg\/L or ferritin 100\u2013299 \u03bcg\/L and transferrin saturation &amp;lt;20%. After 12 months of follow-up, 119 (32%) had ID of the 368 patients who had complete iron data both at baseline and after 12 months and did not receive intravenous (i.v.) iron during follow-up. During the first year after HF diagnosis, 19% had persistent ID, 13% developed ID, 11% resolved ID, and 57% never had ID, consequently 24% changed their classification. Anaemia at baseline was the strongest independent predictor of ID 1 year after diagnosis [odds ratio (OR) 3.91, 95% confidence interval (CI) 1.88\u20138.13, P &amp;lt; 0.001], followed by HF hospitalization (OR 2.21, 95% CI 1.24\u20133.95, P &amp;lt; 0.01), female sex (OR 2.04, 95% CI 1.25\u20133.32, P &amp;lt; 0.01), HFpEF (OR 1.96, 95% CI 1.13\u20133.39, P &amp;lt; 0.05), and diabetes mellitus (OR 1.92, 95% CI 1.06\u20133.48, P &amp;lt; 0.05). ID was associated with low QoL at baseline (MLHFQ score mean difference 7.4 points, 95% CI 3.1\u201311.7, P &amp;lt; 0.001), but not at follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>About one third of patients with new onset HF had ID both at the time of HF diagnosis and after 1 year, though a quarter of the patients changed their ID status. Patients with anaemia, HF hospitalization, female gender, HFpEF, or diabetes mellitus at baseline were more likely to have ID after 1 year implying that these should be carefully screened for ID to find those in need of i.v. iron treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14849","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T02:04:21Z","timestamp":1716861861000},"page":"2661-2671","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Iron Deficiency in New Onset Heart Failure: Association with Clinical Factors and Quality of Life"],"prefix":"10.1093","volume":"11","author":[{"given":"Carin Corovic","family":"Cabrera","sequence":"first","affiliation":[{"name":"Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, S\u00f6dersjukhuset , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Ekstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Division of Cardiovascular Medicine, Karolinska Institutet, Danderyd Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Tornvall","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, S\u00f6dersjukhuset , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"L\u00f6fstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Frisk","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, Science for Life Laboratory, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Linde","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Hage","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Persson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Division of Cardiovascular Medicine, Karolinska Institutet, Danderyd Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kan","family":"Wall\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Division of Cardiovascular Medicine, Karolinska Institutet, Danderyd Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Persson","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, Science for Life Laboratory, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Lyng\u00e5","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, S\u00f6dersjukhuset , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"2026012113142751800_ehf214849-bib-0001","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"key":"2026012113142751800_ehf214849-bib-0002","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/eurheartj\/ehq158","article-title":"Iron deficiency: an ominous sign in patients with systolic chronic heart failure","volume":"31","author":"Jankowska","year":"2010","journal-title":"Eur Heart J"},{"key":"2026012113142751800_ehf214849-bib-0003","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s00392-016-1073-y","article-title":"Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: the PrEP registry","volume":"106","author":"von Haehling","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"2026012113142751800_ehf214849-bib-0004","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"2026012113142751800_ehf214849-bib-0005","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012113142751800_ehf214849-bib-0006","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/s0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2026012113142751800_ehf214849-bib-0007","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/s0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"2026012113142751800_ehf214849-bib-0008","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/ejhf.2810","article-title":"Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis","volume":"25","author":"Graham","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113142751800_ehf214849-bib-0009","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113142751800_ehf214849-bib-0010","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"2023","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026012113142751800_ehf214849-bib-0011","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/ejhf.2251","article-title":"Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure","volume":"24","author":"Graham","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113142751800_ehf214849-bib-0012","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/ejhf.2879","article-title":"Iron deficiency in heart failure: screening, prevalence, incidence and outcome data from the Swedish heart failure registry and the Stockholm CREAtinine measurements collaborative project","volume":"25","author":"Lindberg","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113142751800_ehf214849-bib-0013","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1002\/ehf2.13617","article-title":"Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype","volume":"8","author":"Fitzsimons","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012113142751800_ehf214849-bib-0014","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/ejhf.599","article-title":"Rationale and design of the PREFERS (preserved and reduced ejection fraction epidemiological regional study) Stockholm heart failure study: an epidemiological regional study in Stockholm county of 2.1 million inhabitants","volume":"18","author":"Linde","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012113142751800_ehf214849-bib-0015","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/ehf2.13922","article-title":"Baseline characteristics of 547 new onset heart failure patients in the PREFERS heart failure study","volume":"9","author":"Linde","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026012113142751800_ehf214849-bib-0016","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/1071-9164(95)90025-x","article-title":"Use of the living with heart failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death","volume":"1","author":"Rector","year":"1995","journal-title":"J Card Fail"},{"key":"2026012113142751800_ehf214849-bib-0017","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/eurjhf\/hft083","article-title":"Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status","volume":"15","author":"Com\u00edn-Colet","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026012113142751800_ehf214849-bib-0018","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.117.004519","article-title":"Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients","volume":"11","author":"Grote Beverborg","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026012113142751800_ehf214849-bib-0019","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.jacc.2011.04.040","article-title":"Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival","volume":"58","author":"Okonko","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026012113142751800_ehf214849-bib-0020","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jacc.2021.11.039","article-title":"Criteria for iron deficiency in patients with heart failure","volume":"79","author":"Masini","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026012113142751800_ehf214849-bib-0021","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113142751800_ehf214849-bib-0022","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/hae.12778","article-title":"Classification and regression tree analysis vs. multivariable linear and logistic regression methods as statistical tools for studying haemophilia","volume":"21","author":"Henrard","year":"2015","journal-title":"Haemophilia"},{"key":"2026012113142751800_ehf214849-bib-0023","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/ejhf.2338","article-title":"Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish heart failure registry","volume":"23","author":"Becher","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113142751800_ehf214849-bib-0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcrp.2023.200197","article-title":"Lower low density lipoprotein cholesterol associates to higher mortality in non-diabetic heart failure patients","volume":"18","author":"Gouveia","year":"2023","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"2026012113142751800_ehf214849-bib-0025","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1054\/jcaf.2002.0804216","article-title":"Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure","volume":"8","author":"Horwich","year":"2002","journal-title":"J Card Fail"},{"key":"2026012113142751800_ehf214849-bib-0026","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1002\/ejhf.2949","article-title":"Prognostic value of three iron deficiency definitions in patients with advanced heart failure","volume":"25","author":"Papadopoulou","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113142751800_ehf214849-bib-0027","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"key":"2026012113142751800_ehf214849-bib-0028","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1056\/NEJMe2308305","article-title":"Treating iron deficiency in heart failure","volume":"389","author":"Martens","year":"2023","journal-title":"N Engl J Med"},{"key":"2026012113142751800_ehf214849-bib-0029","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.1093\/eurheartj\/ehad586","article-title":"Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis","volume":"44","author":"Ponikowski","year":"2023","journal-title":"Eur Heart J"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/5\/2661\/64515752\/eschf_11_5_2661.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/5\/2661\/64515752\/eschf_11_5_2661.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:16:11Z","timestamp":1769019371000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/5\/2661\/8271222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,27]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14849","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"2023-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}